On March 30, 2021, Oncotarget published "The Presence of Polymorphisms in Genes Controlling Neurotransmitter Metabolism and Disease Prognosis in Patients with Prostate Cancer: A Possible Link with Schizophrenia," an open-access article reporting that polymorphisms of neurotransmitter metabolism genes had been studied in patients with prostate cancer (PC) characterized by either reduced or extended serum prostate-specific antigen (PSA) doubling time corresponding to unfavorable and favorable disease prognosis respectively. The following gene polymorphisms known to be associated with neuropsychiatric disorders were investigated: the STin2 VNTR in the serotonin transporter SLC6A4 gene; the 30-bp VNTR in the monoamine oxidase A MAOA gene; the Val158Met polymorphism in the catechol-ortho-methyltransferase COMT gene; and the promoter region C-521T polymorphism and the 48 VNTR in the third exon of the dopamine receptor DRD4 gene.